W-C Chou
Overview
Explore the profile of W-C Chou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
922
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu W, Lin S, Shih M, Su C, Wang Y, Lin S, et al.
Clin Microbiol Infect
. 2020 Feb;
26(11):1555.e9-1555.e14.
PMID: 32061794
Objectives: Evidence of false-positive galactomannan enzyme immunoassay (GM-EIA) results associated with intravenous immunoglobulin (IVIG) administration is scarce. Here, we aimed to determine the false-positive rate of GM-EIA after IVIG administration...
2.
Donaldson G, Ladinsky M, Yu K, Sanders J, Yoo B, Chou W, et al.
Science
. 2018 May;
360(6390):795-800.
PMID: 29724905
The immune system responds vigorously to microbial infection while permitting lifelong colonization by the microbiome. Mechanisms that facilitate the establishment and stability of the gut microbiota remain poorly described. We...
3.
Hou H, Lu J, Lin T, Tsai C, Chou W, Lin C, et al.
Blood Cancer J
. 2017 Jul;
7(7):e588.
PMID: 28753595
Suppressor of cytokine signaling 1 (SOCS1) protein, which encodes a member of signal transducers and activators of transcription-induced inhibitors, takes part in a negative regulation of cytokine signaling. The mechanism...
4.
Lim K, Chang Y, Chiang Y, Lin H, Chang C, Lin C, et al.
Blood Cancer J
. 2016 Oct;
6(10):e481.
PMID: 27716741
CALR mutations are identified in about 30% of JAK2/MPL-unmutated myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET) and primary myelofibrosis. Although the molecular pathogenesis of CALR mutations leading to MPNs has...
5.
Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, et al.
Leukemia
. 2016 Apr;
30(7):1485-92.
PMID: 27055875
A number of patient-specific and leukemia-associated factors are related to the poor outcome in older patients with acute myeloid leukemia (AML). However, comprehensive studies regarding the impact of genetic alterations...
6.
Chiu Y, Tsai M, Chou W, Liu Y, Kuo Y, Hou H, et al.
Leukemia
. 2015 Sep;
30(2):274-84.
PMID: 26376228
Distinct microRNA (miRNA) and mRNA signatures were reported in nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML). However, it remains unknown whether the mutation participates in the dynamic interaction between miRNA and...
7.
Hou H, Chou W, Kuo Y, Liu C, Lin L, Tseng M, et al.
Blood Cancer J
. 2015 Aug;
5:e331.
PMID: 26230955
The TP53 mutation is frequently detected in acute myeloid leukemia (AML) patients with complex karyotype (CK), but the stability of this mutation during the clinical course remains unclear. In this...
8.
Lim K, Chang Y, Gon-Shen Chen C, Lin H, Wang W, Chiang Y, et al.
Blood Cancer J
. 2015 Mar;
5:e295.
PMID: 25794131
No abstract available.
9.
Chuang M, Chiu Y, Chou W, Hou H, Chuang E, Tien H
Leukemia
. 2014 Nov;
29(5):1051-9.
PMID: 25428263
As a highly heterogeneous disease, acute myeloid leukemia (AML) needs fine risk stratification to get an optimal outcome of patients. MicroRNAs have florid biological functions and have critical roles in...
10.
Inoue D, Kitaura J, Matsui H, Hou H, Chou W, Nagamachi A, et al.
Leukemia
. 2014 Oct;
29(4):847-57.
PMID: 25306901
Mutations in ASXL1 are frequent in patients with myelodysplastic syndrome (MDS) and are associated with adverse survival, yet the molecular pathogenesis of ASXL1 mutations (ASXL1-MT) is not fully understood. Recently,...